• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ITOS

ITOS

iTeos Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD10.15

+0.02 (+0.20%)

Company Profile

CEO

Michel Detheux

IPO Date

2020-07-24

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.15

Prev. Close

$10.13

Day Low

$10.15

Day High

$10.15

52W Low

$4.80

52W High

$17.63

Market Cap

$0.45B

Volume

11.01M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

63.8%

Avg Negative

1.6%

Avg Neutral

34.8%

News Feed

iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

GlobeNewsWire·7/8/2021·↑ positive

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

Zacks Investment Research·6/15/2021·↑ positive

Why iTeos Therapeutics Stock Soared Today

The Motley Fool·6/14/2021·↑ positive

Why iTeos Therapeutics Shares Are Surging Today

Benzinga·6/14/2021·↑ positive

ITOS Stock Price: Over 40% Increase Pre-Market Details

Pulse2·6/14/2021·↑ positive

iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK

Benzinga·6/14/2021·↑ positive

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

GlobeNewsWire·6/14/2021·↑ positive

iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/14/2021·↓ negative

iTeos Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewsWire·5/13/2021·↑ positive

iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

GlobeNewsWire·4/10/2021·↑ positive